260 related articles for article (PubMed ID: 1718158)
1. Prevalence, characteristics and significance of ventricular premature complexes and ventricular tachycardia detected by 24-hour continuous electrocardiographic recording in the Cardiac Arrhythmia Suppression Trial. CAST Investigators.
Denes P; Gillis AM; Pawitan Y; Kammerling JM; Wilhelmsen L; Salerno DM
Am J Cardiol; 1991 Oct; 68(9):887-96. PubMed ID: 1718158
[TBL] [Abstract][Full Text] [Related]
2. Recruitment and baseline description of patients in the Cardiac Arrhythmia Pilot Study. The Cardiac Arrhythmia Pilot Study (CAPS) investigators.
Am J Cardiol; 1988 Apr; 61(10):704-13. PubMed ID: 2451414
[TBL] [Abstract][Full Text] [Related]
3. Interaction of baseline characteristics with the hazard of encainide, flecainide, and moricizine therapy in patients with myocardial infarction. A possible explanation for increased mortality in the Cardiac Arrhythmia Suppression Trial (CAST).
Anderson JL; Platia EV; Hallstrom A; Henthorn RW; Buckingham TA; Carlson MD; Carson PE
Circulation; 1994 Dec; 90(6):2843-52. PubMed ID: 7994829
[TBL] [Abstract][Full Text] [Related]
4. Relation of baseline characteristics to suppression of ventricular arrhythmias during placebo and active antiarrhythmic therapy in patients after myocardial infarction.
Anderson JL; Hallstrom AP; Griffith LS; Ledingham RB; Reiffel JA; Yusuf S; Barker AH; Fowles RE; Young JB
Circulation; 1989 Mar; 79(3):610-9. PubMed ID: 2465099
[TBL] [Abstract][Full Text] [Related]
5. Effects of encainide, flecainide, imipramine and moricizine on ventricular arrhythmias during the year after acute myocardial infarction: the CAPS.
Cardiac Arrhythmia Pilot Study (CAPS) Investigators
Am J Cardiol; 1988 Mar; 61(8):501-9. PubMed ID: 2894169
[TBL] [Abstract][Full Text] [Related]
6. Predicting mortality after myocardial infarction from the response of RR variability to antiarrhythmic drug therapy.
Bigger JT; Rolnitzky LM; Steinman RC; Fleiss JL
J Am Coll Cardiol; 1994 Mar; 23(3):733-40. PubMed ID: 7509355
[TBL] [Abstract][Full Text] [Related]
7. Treatment of ventricular arrhythmias after CAST.
Tonkin AM
Med J Aust; 1992 Apr; 156(7):488-92. PubMed ID: 1372950
[TBL] [Abstract][Full Text] [Related]
8. Events in the cardiac arrhythmia suppression trial: baseline predictors of mortality in placebo-treated patients.
Capone RJ; Pawitan Y; el-Sherif N; Geraci TS; Handshaw K; Morganroth J; Schlant RC; Waldo AL
J Am Coll Cardiol; 1991 Nov; 18(6):1434-8. PubMed ID: 1939943
[TBL] [Abstract][Full Text] [Related]
9. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.
Cardiac Arrhythmia Suppression Trial (CAST) Investigators
N Engl J Med; 1989 Aug; 321(6):406-12. PubMed ID: 2473403
[TBL] [Abstract][Full Text] [Related]
10. The Cardiac Arrhythmia Suppression Trial: first CAST ... then CAST-II.
Greene HL; Roden DM; Katz RJ; Woosley RL; Salerno DM; Henthorn RW
J Am Coll Cardiol; 1992 Apr; 19(5):894-8. PubMed ID: 1552108
[TBL] [Abstract][Full Text] [Related]
11. Significance of arrhythmias during the first 24 hours of acute myocardial infarction treated with alteplase and effect of early administration of a beta-blocker or a bradycardiac agent on their incidence.
Heidbüchel H; Tack J; Vanneste L; Ballet A; Ector H; Van de Werf F
Circulation; 1994 Mar; 89(3):1051-9. PubMed ID: 8124790
[TBL] [Abstract][Full Text] [Related]
12. Events in the Cardiac Arrhythmia Suppression Trial (CAST): mortality in patients surviving open label titration but not randomized to double-blind therapy.
Wyse DG; Hallstrom A; McBride R; Cohen JD; Steinberg JS; Mahmarian J
J Am Coll Cardiol; 1991 Jul; 18(1):20-8. PubMed ID: 1904892
[TBL] [Abstract][Full Text] [Related]
13. [New aspects of the clinical use of anti-arrhythmia agents with special reference to acute therapy of ventricular tachycardia (lidocaine vs. ajmaline)].
Manz M; Mletzko R; Jung W; Lüderitz B
Herz; 1990 Apr; 15(2):79-89. PubMed ID: 2188894
[TBL] [Abstract][Full Text] [Related]
14. Increased risk of death and cardiac arrest from encainide and flecainide in patients after non-Q-wave acute myocardial infarction in the Cardiac Arrhythmia Suppression Trial. CAST Investigators.
Akiyama T; Pawitan Y; Greenberg H; Kuo CS; Reynolds-Haertle RA
Am J Cardiol; 1991 Dec; 68(17):1551-5. PubMed ID: 1720917
[TBL] [Abstract][Full Text] [Related]
15. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.
Echt DS; Liebson PR; Mitchell LB; Peters RW; Obias-Manno D; Barker AH; Arensberg D; Baker A; Friedman L; Greene HL
N Engl J Med; 1991 Mar; 324(12):781-8. PubMed ID: 1900101
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of class IC antiarrhythmic agents for the treatment of coexisting supraventricular and ventricular tachycardia.
Rinkenberger RL; Naccarelli GV; Berns E; Dougherty AH
Am J Cardiol; 1988 Aug; 62(6):44D-55D. PubMed ID: 3136636
[TBL] [Abstract][Full Text] [Related]
17. The natural history of benign and potentially malignant ventricular arrhythmias with special reference to nonsustained ventricular tachycardia.
Pratt CM; Francis M; Mahler S; Aogaichi K; Keus P; Young JB
Am Heart J; 1988 Oct; 116(4):897-903. PubMed ID: 2459950
[TBL] [Abstract][Full Text] [Related]
18. Implications of the Cardiac Arrhythmia Suppression Trial for antiarrhythmic drug treatment.
Bigger JT
Am J Cardiol; 1990 Feb; 65(8):3D-10D; discussion 68D-71D. PubMed ID: 2106253
[TBL] [Abstract][Full Text] [Related]
19. [Unsustained ventricular tachycardia and accelerated idioventricular rhythm--clinical and electrocardiographic features].
Abreu P; Fernandes A; Ventosa A; Adragão P; Bonhorst D; Seabra-Gomes R
Rev Port Cardiol; 1992; 11(7-8):641-8. PubMed ID: 1389302
[TBL] [Abstract][Full Text] [Related]
20. Mortality following ventricular arrhythmia suppression by encainide, flecainide, and moricizine after myocardial infarction. The original design concept of the Cardiac Arrhythmia Suppression Trial (CAST).
Epstein AE; Hallstrom AP; Rogers WJ; Liebson PR; Seals AA; Anderson JL; Cohen JD; Capone RJ; Wyse DG
JAMA; 1993 Nov; 270(20):2451-5. PubMed ID: 8230622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
